Four 20 Pharma: six strains from Paderborn and four registration designations

Who is Four 20 Pharma and where does its raw material come from?

Four 20 Pharma GmbH is based in Paderborn, Germany, and in Poland, it operates as the entity responsible for the pharmaceutical raw material dispensed by prescription. On its own website, it describes itself as an importer and wholesaler of medical hemp, working with certified suppliers, rather than as a grower.

On the Polish product card, the responsible entity is listed as FOUR 20 PHARMA GMBH with an address at Friedrich-List-Strasse 67 in Paderborn, the form is dried flower, and the dispensing category is Rpw. The company's website lists a GDP certificate and a GMP certificate, along with three German permits: a manufacturing permit under paragraph 13 of the Medicines Act, a wholesale trading permit under paragraph 52a of the same act, and a narcotics permit under paragraph 3 of the Drug Act.

The company is currently owned by Curaleaf. The majority stake was announced in August 2022 and closed a month later, and a statement from April 30, 2026, mentions the acquisition of the remaining shares and that the Four 20 brand is entering, among other markets, the Polish market. The same statement cites Paderborn as the location where one hundred and ten people work.

One thing could not be determined: where the material that reaches Polish products physically grows. The company's website talks about the role of the importer and suppliers, while the owner's statement refers to it as a producer conducting cultivation. These two descriptions cannot be reconciled without a document that neither party publishes, leaving the cultivation country unknown.

Which strains of Four 20 Pharma are available in Polish pharmacies?

Six: Frozen Lemon Mints, Gastro Pop, GMO, Gorilla Glue, Mac 1, and Masterpiece. Each corresponds to exactly one entry in our pharmacy listing, so none are listed by this producer in two parallel declarations at once. Four of these names have no other supplier in Poland.

The last column counts pharmacy entries for the entire name, across all suppliers at once, not just for Four 20 Pharma itself. This producer has one entry for each of the six strains, so the four next to Gorilla Glue refers to the three other entities. The names in the table have their own descriptions in this cluster, which we refer to separately. The current list of what is available in pharmacies in a given month is maintained by a summary of available strains, and it is there, not here, that the variable numbers can be found. The store category dried hemp includes products available over the counter and does not contain pharmacy items described in this text.

The name of the strain itself does not indicate the manufacturer. Gorilla Glue four entities lead in this comparison, and Mac 1 two, so a patient who remembers the name will receive a position from a specific supplier at the pharmacy, not a strain as a concept. The remaining four, namely Frozen Lemon Mints, Gastro Pop, GMO and Masterpiece, appears in our data exclusively from this manufacturer. With these four, the strain name indeed indicates one source, while the first two do not indicate any.

Why does one registration designation cover several strains at once?

Because the designation describes the declared content, not the plant. For this manufacturer, our profile data shows four designations differing only by the number entered in the middle of the name, and one of them covers as many as four strains. Therefore, the prescription pertains to the registration item, not the trade name.

The registration name is Cannabis flos Four 20 Pharma and carries a numerical component, which we do not transcribe here, as it is a declared value with its own margin, not a measurement result of the batch. Under one of these designations are Frozen Lemon Mints, Gastro Pop, GMO, and Masterpiece. Two strains, GMO and Mac 1, have two different designations in our data, and Gorilla Glue also has two.

The confusion is compounded by the entries in the databases. Two items from Mac 1 assigned to this manufacturer bear the name of a completely different brand in the title, although the producer field indicates Four 20 Pharma. Therefore, the title in the profile database is not an identifier on which a comparison can be based, and the same applies to the strain name added to the label by sellers.

The practical conclusion is one. From the registration designation, it is impossible to read which of the four strains the pharmacy will provide upon fulfilling the prescription, because from the registry's point of view, these are variants of the same item. Anyone wanting to compare two purchases must look at the strain name added by the pharmacy, which does not come from an official document.

How does the raw material from this manufacturer differ from that of others?

By the documentation of trade, not the plant itself. The company declares GMP and GDP certificates and German permits for production and trade, which describe the handling of the goods, not the properties of the dried flower. No open source provides the analysis result for the series introduced to Polish pharmacies.

It is important to distinguish this right away, as both layers refer to different things. The good manufacturing practice certificate and the good distribution practice certificate concern the conditions of production, storage, and transport. The Polish item card adds to this the category of dispensing, form, and sizes of packaging, with the smallest weighing five grams. All of this is verifiable facts in the document and does not provide any information about the composition of a specific batch.

The second layer is the manufacturer's material. In July 2024, an American lifestyle magazine published an interview in which the company describes its own cultivation, drying on hangers, and manual trimming, and also provides one number for the terpene content in a specific batch of Gastro Pop. The interview pertains to the German market and is the company's statement about itself, so we treat it as a declaration, not as documentation of Polish items.

The answer to the question in the header is therefore cautious. At a verifiable level, this manufacturer does not differ from the others in anything measurable: it has the same trade certificates and the same dispensing category. The differences it mentions itself have no public confirmation.

What do profile sources say about the composition of these six strains?

Rarely the same. Four out of six strains have a designation in our data indicating that two Polish services provide them with different compositions, while the remaining two are described by only one source. None has received a description consistent in both databases, which is a result in itself for a single supplier's catalog.

This is best seen on Masterpiece. One database lists four compounds for this strain: caryophyllene, limonene, linalool, and myrcene. The other provides one, limonene, and ends the description there. It is not about a difference in order or rounding, but rather that one source sees a four-component profile, while the other sees a one-component profile for the same pharmacy item.

The numbers that the first of these databases assigns to individual compounds of Masterpiece add up to 59, not 100. For the other items from this manufacturer, the same sums range from 64 to 88 and also do not reach one hundred. Since the denominator is unknown and different each time, we present the composition as a list of compounds, not as shares, because a share without a denominator appears to be a measurement, which it is not.

The situation is similar with genetics. For all six strains, our data records discrepancies between services: one records the strain as a hybrid, while the other adds indica or sativa dominance. Six out of six is not a case of a single page, but rather a way in which these descriptions are created.

What is known and what is not known about the raw material from this producer?

It is known who is responsible for this raw material, in what category it is dispensed, and under what designations it stands on the pharmacy shelf. However, it is not known where the material for Polish items grows or what the analyses of individual series have shown, as none of the available sources publish this data.

The documents reveal little, but firmly. The card for the Polish item provides the responsible entity with a full address in Paderborn, the form, and the Rpw category, as well as the sizes of packaging. The company's website lists trade certificates and the numbers of regulations on which it bases its permits. The owner's stock exchange announcement from April 2026 closes the ownership structure. This is all that can be verified without asking the company for consent.

Separately stands what is a narrative. An interview in a lifestyle magazine, descriptions of aroma, and fields with possible effects in Polish profile databases are editorial classifications, not research results. These databases do not state where they obtain their lists of compounds, and that is precisely why two of them can describe the same item differently.

However, we did not find three things: a certificate of analysis for any batch sold in Poland, information about the country of cultivation, and a description of the method used to measure terpenes. The absence of these three items is not an accusation against the manufacturer, as the law does not require them to be published. It is, however, a limit to what can be written honestly about this raw material.

Why does the availability of these strains change over time?

Because the pharmacy catalog is not a fixed list. In our data record, two entries from this manufacturer have a status indicating a lack of goods, while the others have a status of high availability. This state describes only the moment of data retrieval and can change in both directions between subsequent retrievals.

The mechanism is simple to describe. The permit for circulation pertains to the registration entry and lasts regardless of whether the goods are currently in stock, while delivery depends on the release of the batch, transport, and control. Therefore, a strain can be listed in the registry at all times while simultaneously disappearing from the shelf for weeks, which may appear to the patient as a withdrawal, although it is not. It can also happen the other way around: an entry returns to sale without any announcement, and the patient only finds out about it at the counter.

That is why this text does not contain a statement that a particular strain is available. The current state leads a summary of available strains, updated separately, and the producer's page describes what does not change from month to month: who is responsible for the raw material, how it is documented, and what is unknown about it. This text is meant to be true even in six months, so it describes the market structure, not the stock status on the day of publication.

What adverse effects have been reported after using this producer's raw material?

None separately. We did not find a summary that would attribute reports to this manufacturer or any of its six strains. Polish supervision links the report to the medicinal product and batch number, not to the trade name of the plant, so breaking down such data by individual suppliers simply does not occur.

Reports of adverse effects are collected for medicinal products with a batch number, not for the strain name, so the following pertains to hemp dried flower as a group of raw materials. The most frequently reported symptoms are dry mouth, red eyes, and increased heart rate. Dizziness upon rapid standing, daytime drowsiness, and temporary worsening of short-term memory are less frequently described, as well as anxiety that increases with dosage. A separate issue is medications taken concurrently, especially sedatives and those affecting coagulation: their assessment requires knowledge of the entire list of preparations, not just the description of the plant. We do not provide the frequency of these symptoms numerically, as public compilations for hemp dried flower in Poland do not separate them by individual products.

This has one practical consequence for this particular manufacturer. Since four of its strains are listed under a common registration designation, even a report described by the batch number will not clearly indicate which one the patient was taking. A report can be submitted by the patient, caregiver, or a medical professional, and it is received by the registration office and the responsible entity.

Frequently asked questions about Four 20 Pharma strains

Who is responsible for the Four 20 Pharma raw material sold in Polish pharmacies?

The responsible entity listed on the card for the Polish entry is FOUR 20 PHARMA GMBH with an address in Paderborn. Since April 2026, the company has been wholly owned by Curaleaf, which previously held a majority stake in it.

How many strains from this manufacturer are included in this summary?

Six: Frozen Lemon Mints, Gastro Pop, GMO, Gorilla Glue, Mac 1, and Masterpiece. Each corresponds to exactly one pharmacy entry, so the manufacturer does not maintain any of them in two parallel declarations.

Does Four 20 Pharma cultivate hemp itself?

It has not been established. The company's own website describes it as an importer and wholesaler working with certified suppliers, while the owner's statement from 2026 refers to it as a producer conducting cultivation. None of these sources indicate the country of cultivation for Polish entries.

Is the strain name alone enough to obtain this raw material at the pharmacy?

No. The prescription pertains to the registration entry, and the strain name is a commercial description added by industry services and pharmacies. Four strains from this manufacturer are listed in our data under the same registration designation.

Have results of batch analysis been published for this manufacturer's strains?

We did not find such a publication. Neither the company's website nor Polish profile services provide an analysis certificate for the batch introduced into circulation in Poland, so the declaration from the packaging remains the only number the patient sees.

Why do the composition descriptions of Masterpiece differ between services?

Because they are based on different foundations. One Polish database lists four compounds for this strain, another provides only limonene, and none publish the raw analysis result on which they could rely.

Dried flower is a pharmaceutical raw material dispensed by prescription in the Rpw category, and this material is for informational purposes only and does not replace medical consultation. The editorial text was prepared by u Bucha editorial.